OPKO Health (NASDAQ:OPK) Stock Price Up 4.7%

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) shares rose 4.7% on Friday . The stock traded as high as $1.67 and last traded at $1.67. Approximately 499,074 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 8,050,323 shares. The stock had previously closed at $1.59.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. StockNews.com raised shares of OPKO Health to a "sell" rating in a research note on Saturday, July 27th. Piper Sandler reduced their target price on shares of OPKO Health from $5.00 to $3.00 and set an "overweight" rating on the stock in a research note on Thursday, July 18th. Barrington Research lifted their price objective on shares of OPKO Health from $1.50 to $2.25 and gave the stock an "outperform" rating in a research note on Thursday, August 8th. Finally, HC Wainwright reissued a "buy" rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, May 8th.

OPKO Health Stock Up 5.7 %

The company has a quick ratio of 1.62, a current ratio of 1.91 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -4.80 and a beta of 1.65. The stock's fifty day moving average price is $1.43 and its 200-day moving average price is $1.27.

OPKO Health (NASDAQ:OPK - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.08. The company had revenue of $182.20 million for the quarter, compared to the consensus estimate of $184.70 million. OPKO Health had a negative net margin of 31.44% and a negative return on equity of 17.89%. The firm's revenue was down 31.3% compared to the same quarter last year. During the same period last year, the company earned ($0.03) earnings per share. On average, sell-side analysts predict that OPKO Health, Inc. will post -0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Opko Health, Inc. sold 50,000 shares of the business's stock in a transaction on Monday, July 1st. The shares were sold at an average price of $26.63, for a total transaction of $1,331,500.00. Following the transaction, the insider now directly owns 3,508,603 shares in the company, valued at $93,434,097.89. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last three months, insiders have sold 736,644 shares of company stock worth $23,874,134. Insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

Institutional investors and hedge funds have recently modified their holdings of the stock. Rubric Capital Management LP boosted its position in shares of OPKO Health by 800.0% in the second quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company's stock valued at $55,528,000 after acquiring an additional 39,486,490 shares during the period. Y.D. More Investments Ltd bought a new stake in shares of OPKO Health in the second quarter valued at about $1,840,000. Assenagon Asset Management S.A. boosted its position in shares of OPKO Health by 107.2% in the first quarter. Assenagon Asset Management S.A. now owns 1,253,808 shares of the biotechnology company's stock valued at $1,502,000 after acquiring an additional 648,569 shares during the period. Squarepoint Ops LLC bought a new stake in shares of OPKO Health in the second quarter valued at about $592,000. Finally, Lazard Asset Management LLC bought a new stake in OPKO Health during the first quarter worth about $258,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.